SCHEMBL465593

SCHEMBL465593

CC(=O)OC([C]=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
CYP3A4 P08684 1/20 0.51
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
PABPC1 P11940 1/20 0.44
APOBEC3A P31941 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.40
HPGD P15428 1/20 0.39
MAPK1 P28482 2/20 0.39
CYP2D6 P10635 1/20 0.39
SRC P12931 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
LMNA P02545 2/20 0.38
CYP19A1 P11511 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7225521 1.00 ALDH1A1 (0.51) ALDH1A1CYP3A4KMT2AMEN1PABPC1
SCHEMBL28807320 0.83 LMNA (0.42) ALDH1A1CYP3A4KMT2AMEN1LMNA
SCHEMBL10402999 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4KMT2AMEN1PABPC1
SCHEMBL7699172 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4KMT2AMEN1PABPC1
SCHEMBL2835326 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4KMT2AMEN1PABPC1
SCHEMBL18367774 0.83 ALDH1A1 (0.50) ALDH1A1CYP3A4KMT2AMEN1PABPC1
SCHEMBL7765460 0.81 CYP3A4 (0.45) ALDH1A1CYP3A4KMT2AMEN1TSHR
SCHEMBL11301580 0.80 KMT2A (0.52) ALDH1A1CYP3A4KMT2AMEN1PABPC1
SCHEMBL11516703 0.80 ELANE (0.39) ALDH1A1CYP3A4KMT2AMEN1TSHR
SCHEMBL27418681 0.79 SRC (0.39) ALDH1A1CYP3A4KMT2ATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2755983-B1 SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC (US) 2017-03-15 EP claimed
US-9403863-B2 Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections IDENIX PHARMACEUTICALS LLC (US) 2016-08-02 US claimed
US-4269773-A CEPHALOSPORINS SHIONOGI & CO., LTD. (JP) 1981-05-26 US claimed
US-4267340-A BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-05-12 US claimed
US-3993646-A Process for the ring expansion of penicillins to cephalosporin compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-11-23 US claimed
WO-2024145662-A1 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS ALTAY THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed
WO-2024112705-A1 BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS ELIMA THERAPEUTICS, INC. (US) 2024-05-30 WO disclosed
US-20240101562-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME HOLOSMEDIC (KR) 2024-03-28 US disclosed
US-11866515-B2 Hemiasterlin derivatives for conjugation and therapy SUTRO BIOPHARMA, INC. (US) 2024-01-09 US disclosed
EP-3131914-B1 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS LLC (US) 2023-05-10 EP disclosed
US-20230139442-A1 MODIFIED AMINO ACIDS SUTRO BIOPHARMA, INC. 2023-05-04 US disclosed
EP-4174068-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME Holosmedic (KR) 2023-05-03 EP disclosed
US-4107431-A ANTIBIOTICS GLAXO LABORATORIES LIMITED (GB) 1978-08-15 US disclosed
US-4091210-A Preparation of 3-alkyl-3-cephem-4-carboxylic acid compounds from dithio isopropenyl azetidine carboxylic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1978-05-23 US disclosed
US-4084049-A CEPHALOSPORIN ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1978-04-11 US disclosed
US-4045435-A Preparation of cephalosporin ethers ELI LILLY AND COMPANY (US) 1977-08-30 US disclosed
US-4014872-A ANTIBIOTICS GLAXO LABORATORIES LIMITED (EN) 1977-03-29 US disclosed
US-3984397-A CYCLIZATION FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-10-05 US disclosed
US-3954732-A BACTERICIDAL PENICILLINS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-05-04 US disclosed
US-3953438-A Preparation of cephalosporin ethers ELI LILLY AND COMPANY (US) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866515-B2 Hemiasterlin derivatives for conjugation and therapy CYP17A1, HSD17B7, SHBG ALDH1A1 1882/4885CYP3A4 545/4885KMT2A 2712/4885
US-20240101562-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME SLC11A2, ABCC1, TSG101 ALDH1A1 3381/4885CYP3A4 4743/4885KMT2A 3627/4885
US-20230139442-A1 MODIFIED AMINO ACIDS PTMS, DNPEP, ANPEP ALDH1A1 2116/4885CYP3A4 4714/4885KMT2A 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.